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A study is currently in progress at St Bartholomew's
Hospital in which patients with B-cell lymphoma receive
cyclophosphamide and total body irradiation supported by
autologous bone marrow transplantation. The marrow is
being treated in vitro with the monoclonal antibody anti-B1
(Coulter Immunology) and baby rabbit complement (Pel-
Freez) before re-infusion (Rohatiner et al., 1986).
Anti-B1 is an antibody that defines a 35 kDa B-cell
differentiation antigen (CD20) which is expressed on more
than 95% of normal B-cells isolated from peripheral blood
or lymphoid tissue (Stashenko et al., 1980) and the majority
of tumour cells from patients with B-cell NHL (Anderson et
al., 1984). It has been previously reported that normal bone
marrow may contain up to 5% CD20 positive lymphocytes
(Stashenko et al., 1981) and that this figure is compatible
with absence of bone marrow infiltration by morphological
criteria (Nadler et al., 1984). However, in vitro culture
studies suggest that morphologically normal bone marrow
may contain occult lymphoma cells: in a study of Burkitt
lymphoma (Benjamin et al., 1984) 17% of morphologically
normal bone marrows cultured in vitro gave rise to tumour
cell lines or cells containing the 8:14 translocation.
A number of patients with morphologically normal bone
marrow have been found, on cell surface phenotyping in this
laboratory, to have levels of CD20 positive lymphocytes
greater than 5%. This observation prompted the present
study, the objective of which was first to establish the
normal range of CD20 positive lymphocytes in bone marrow
and subsequently, to compare the levels of CD20 positive
cells in marrow from patients with NHL, before and after
therapy. The levels of other immunological markers were
also evaluated to estimate the significance of possible
artifactual effects which may result from therapy or
peripheral blood contamination.
Bone marrow samples from 20 normal subjects (12 men, 8
women, age range 19-43 years, median 31) and 85 patients
with NHL (49 men, 36 women; age range 12-80 years,
median 53) were studied. The morphological diagnoses are
shown in Table I. Patients were categorised into three groups
according to bone marrow aspirate and trephine morphology
using standard haematological criteria applied in this
laboratory, i.e. those in whom the bone marrow was
uninvolved before or after therapy and those with bone
marrow infiltration.
Table I Morphological diagnoses
Histology No. of cases
Low grade 60
High grade 25
Total 85
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Bone marrow was aspirated from the posterior iliac crest
and added to 10ml of TC199 medium and preservative-free
heparin (100 units). A trephine biopsy was performed on all
patients. The marrow was layered on to lymphoprep
(Nyeegard), density 1.077, and centrifuged at 1,300r.p.m. for
25min at 18°C. The mononuclear cell interface was
harvested and washed twice in phosphate buffered saline
(PBS) containing 5% calf serum and 0.05% sodium azide.
Phenotyping was performed by a modification of standard
methods: 106 cells in 20p1 were incubated with 204u1 of the
test antibody at 2 x working concentration in a 96-well plate
(Limbro, Flow) at 4°C for 30min. The cells were then
washed and incubated with 20pl of the second antibody,
goat anti-mouse FITC (Coulter), for a further 30min at 4°C.
Finally, the cells were washed three times in 5% calf serum
in PBS and resuspended in a final volume of 100pl of
isoton. Each sample was analysed on the day of collection
on an Epics C cell sorter (Coulter Electronics) and the
percentage of positive cells determined after calibration of
the instrument with negative and positive controls.
The following antibodies were used (Table II): anti-B1
(CD20), anti-B4 (CDl9), J5 (CD1O), CA2 (anti-DR), anti-T3
(CD3) and WT1 (CD7) together with a positive control 2D1
(Leucocyte Common Antigen, CD45) and a negative control,
20p1 of 5% calf serum in PBS.
The mean and standard deviations were calculated using
the Mann-Whitney test. The negative background on the
Epics C ranged from 0.1 to 4.0% (the average being 1%,
with only one patient having a background value of 4%).
The Mann-Whitney test was also used to determine whether
there was any significant difference between the results for
previously untreated patients and those who had received
chemotherapy and between those with involved and
uninvolved marrows.
The results are shown in Table III and illustrated in
Figure 1. The data have been pooled for all histological
subtypes of NHL. The number of CD20 positive lympho-
cytes was significantly higher in morphologically involved
marrow than in marrow from normal subjects (mean values
46% vs 8%) (Table III and Figure 1). There was also a
significant difference between uninvolved and morpho-
logically involved marrow (Table IV and Figure 1), the
CD20 value for involved marrow always being greater than
Table II Panel of antibodies used in the study
Antigen
Antibody (CD number) Source Target
Anti-B1 20 Coulter Mature B-cells
Anti-B4 19 Coulter Early B-cell marker
J5 10 Coulter Common ALL antigen
CA2 HLA-DR W. Bodmer HLA-DR antigen
Anti-T3 3 Coulter Mature T-cells
WT1 7 M. Greaves Most peripheral T-cells
and thymocytes
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Table III Immunophenotype (mean+s.e.m.) of bone marrow from normal subjects and patients with NHL
% antibody positive cells
BJ (CD20) B4 (CD19) J5 (CDIO) CA2 (HLA-DR) T3 (CD3) WTI (CD7)
Normal subjects (n=20) 8.2+1.8 9.5+2.1 9.0+2.0 22.7+5.0 19.8+4.4 12.8+2.8
Uninvolved at presentation (n=25) 5.8+1.2 4.4+1.0 6.2+1.5 27.4+6.1 16.3+3.6 15.5+3.3
Uninvolved post-treatment (n=40) 5.8+0.9 5.1+0.9 5.5+1.0 20.2+3.3 15.1+2.7 12.9+2.1
Involved at presentation (n=20) 46.2+10.3 42.0+9.6 18.8+4.7 49.7+12.2 14.7+3.5 9.1+2.3
13% (Figure 1). The same overall pattern applies to
antibodies to CD19 and CA2 which are also expressed by B-
lymphocytes (Table III).
Table IV Statistical comparison
between uninvolved and involved
bone marrow at presentation
Anti-BI P<0.00001
Anti-B4 P<0.00001
J5 n.s.
CA2 P<0.0002
Anti-T3 n.s.
WT1 n.s.
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Figure 1 Levels of CD20 positive lymphocytes in: (a) patients
with involved marrow; (b) normal subjects; (c) patients with no
evidence of bone marrow infiltration at presentation; and (d)
patients with no evidence of bone marrow infiltration after
therapy.
In contrast, there was no significant difference between the
CD20 levels in patients with morphologically normal bone
marrow at presentation and after therapy once complete
remission had been achieved (Table III). The mean
percentage of CD20 positive cells in uninvolved bone
marrow was 5.8 both at presentation and after therapy, the
median values being 5.0 and 4.0, respectively. There was also
no significant difference between the levels of CD19 and
CD1O positive cells at presentation or after treatment if the
bone marrow was morphologically uninvolved. The upper
limit of the CD20+range was 20% for patients (Figure 1)
and 14% for normal subjects.
The objective of this study was to determine the normal
range for CD20 positive cells in bone marrow, in the context
of lymphoma and potential post-chemotherapy effects. This
was established at a level higher than that previously
suggested. A difference was demonstrated between levels of
CD20 positive cells in infiltrated marrow and that of normal
subjects and patients with no evidence of marrow
infiltration.
Antigens defined by the CDl9 and CD1O antibodies are
expressed on cells appearing earlier in B-cell differentiation
than CD20, and it might be expected that they would
therefore be present in increased numbers following
treatment if samples were analysed during active marrow
recovery. This was not the case.
The range of CD20 positive cells was greater in patients
with NHL than in normal subjects. A possible explanation
for this is that the 'excess' CD20 positive cells are the
phenotypic expression of a population of occult lymphoma
cells which appear morphologically normal, the possibility of
peripheral blood contamination being unlikely (Clarke et al.,
1986).
Assessment of the level of CD20 bearing cells is of
importance when considering the efficacy of in vitro
treatment with an antibody such as anti-B1 and complement.
It has been demonstrated that, within the limits of flow
cytofluorometric analysis, CD20 positive cells can be
completely removed from bone marrow, which has a CD20
value in the range of 0-10%, by three cycles of treatment
with anti-B1 and baby rabbit complement (Nadler et al.,
1981). These results have been confirmed in 38 patients with
B-cell malignancy treated at St Bartholomew's Hospital
(unpublished observations). However, immunophenotyping
alone is not sensitive enough to detect very small
populations of neoplastic cells. This is supported by the
results of peripheral blood studies using molecular
techniques in patients with lymphoma (Brada et al., 1987).
Various methods have therefore been proposed to assess
'minimal residual disease' including dual fluorescence,
analysis of specific chromosomal breakpoints (Weiss et al.,
1987), and more recently, molecular techniques using
immunoglobulin and T-cell receptor gene rearrangements
(Brada et al., 1987). Such studies may help in the detection
of morphologically undetectable lymphoma and further
define the efflcacy of in vitro techniques for removal of
tumour cells from bone marrow being used for autologous
transplantation.
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